Pharmaceuticals, Biotechnology and Life Sciences
The global drug discovery network ELRIG has appointed Dr Kelly Gray and Dr Elaine Duncan to its Board, reinforcing leadership...
The global drug discovery network ELRIG has appointed Dr Kelly Gray and Dr Elaine Duncan to its Board, reinforcing leadership across scientific programming and early career initiatives,
Bristol Myers Squibb and Bain Capital announced Monday the creation of a new independent biopharmaceutical company, called NewCo, which will be focused on developing new therapies for autoimmune diseases that...
Antibody-drug conjugates (ADCs) continue to evolve as one of the most promising approaches in targeted cancer therapy, yet the fundamental challenge in advancing solid tumour ADCs remains therapeutic selectivity, not just payload potency, as described in a press release about...
Micrima, a Bristol-based health tech company, is urging women to give themselves the gift of prioritising knowledge of their breast...
Brenntag, the global market leader in chemicals and ingredients distribution, held a celebration to mark its 150-year anniversary yesterday in...
The global drug discovery network ELRIG has appointed Dr Kelly Gray and Dr Elaine Duncan to its Board, reinforcing leadership across scientific programming and early career initiatives,
Antibody-drug conjugates (ADCs) continue to evolve as one of the most promising approaches in targeted cancer therapy, yet the fundamental…
Sandoz posts 7% revenue growth for 2025, driven by 15% biosimilars expansion, and guides for accelerated sales and margin growth in 2026.
Promatix Biosciences presents preclinical data on PBS293-MMAE, a first-in-class bispecific ADC targeting EGFR and EphA2 in colorectal cancer.
South Korean pharmaceutical manufacturers are rapidly expanding capacity to support manufacturing of long‑acting obesity shots, signalling deeper integration with global…
With semaglutide patents nearing expiry in key markets, Indian manufacturers and partners are mobilizing to introduce lower‑cost GLP‑1 alternatives, tapping…
Novo Nordisk’s mid‑stage “triple G” obesity candidate UBT251 showed up to ~19.7 % mean weight loss in a Chinese phase 2…
Novo Nordisk reports up to 19.7% mean weight loss in Phase 2 trial of triple agonist UBT251, expanding its next-generation obesity pipeline.
GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) — Precise Bio, Inc. (“Precise Bio” or the “Company”), a clinical-stage regenerative medicine…
EMERYVILLE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members…
